Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020142646 - CO-ADMINISTRATION OF INHIBITORS TO PRODUCE INSULIN PRODUCING GUT CELLS

Publication Number WO/2020/142646
Publication Date 09.07.2020
International Application No. PCT/US2020/012111
International Filing Date 03.01.2020
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 3/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
A61P 5/50 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
5Drugs for disorders of the endocrine system
48of the pancreatic hormones
50for increasing or potentiating the activity of insulin
CPC
A61K 31/4178
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
4178not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/4409
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4409only substituted in position 4, e.g. isoniazid, iproniazid
A61K 31/501
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
50Pyridazines; Hydrogenated pyridazines
501not condensed and containing further heterocyclic rings
A61K 31/55
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 3/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
Applicants
  • THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US]/[US]
Inventors
  • ACCILI, Domenico
  • KITAMOTO, Takumi
  • LIN, Hua V.
Agents
  • VAN DYKE, Timothy H.
  • MOLINELLI, Eugene J.
Priority Data
62/787,92003.01.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CO-ADMINISTRATION OF INHIBITORS TO PRODUCE INSULIN PRODUCING GUT CELLS
(FR) CO-ADMINISTRATION D'INHIBITEURS POUR PRODUIRE DES CELLULES INTESTINALES PRODUISANT DE L'INSULINE
Abstract
(EN)
Methods are described for producing enteroendocrine cells that make and secrete insulin in a subject by co-administering a Foxo1 inhibitor in combination with a Notch inhibitor or ROCK inhibitor, or both. Also described are pharmaceutical compositions comprising a combination of a Foxo1 inhibitor with a Notch inhibitor or ROCK inhibitor, or both. The described methods and compositions may be used to treat a disorder associated with impaired pancreatic function such as diabetes.
(FR)
L'invention concerne des méthodes permettant de produire des cellules entéroendocrines qui fabriquent et sécrètent de l'insuline chez un sujet en co-administrant un inhibiteur de Foxo1 combiné à un inhibiteur de Notch ou à un inhibiteur de ROCK, ou aux deux. L'invention concerne également des compositions pharmaceutiques comprenant une combinaison d'un inhibiteur de Foxo1 et d'un inhibiteur de Notch ou d'un inhibiteur de ROCK, ou des deux. Les méthodes et compositions de l'invention peuvent être utilisées pour traiter un trouble associé à une altération de la fonction pancréatique, tel que le diabète.
Latest bibliographic data on file with the International Bureau